100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AI138740
Award Date
5/3/19
Completion Date
4/30/21
Dollars Obligated
$355K
Overview
Activity
7
Transactions
7
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Ichor Biologics LLC (K7HRH5JERRB7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Update #1
Update #2
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS
Posted 5/3/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS - PROJECT SUMMARY HANTAVIRUSES ARE AN EMERGING FAMILY OF HIGHLY PATHOGENIC VIRUSES THAT CAUSE 100-200,000 CASES OF TWO SEVERE FEBRILE ILLNESSES A YEAR; HANTAVIRUS CARDIOPULMONARY SYNDROME (HCPS) AND HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS). WHILE THE ANNUAL INCIDENCE OF INFECTIONS ARE RELATIVELY LOW COMPARED TO OTHER VIRAL INFECTIONS, SOME HANTAVIRUS STRAINS ARE PARTICULARLY DEADLY, CAUSING A 35-40% MORTALITY RATE IN OTHERWISE HEALTHY YOUNG ADULTS. IN FACT, BECAUSE OF THEIR HIGH MORTALITY RATES HANTAVIRUSES ARE CONSIDERED A POTENTIAL BIOTERRORISM AGENT BY THE NIH, CDC AND THE DEPARTMENT OF DEFENSE. COUPLED WITH THE FACT THAT THERE IS NO VIRUS-SPECIFIC TREATMENT OR GLOBALLY APPROVED VACCINE TO PROTECT AGAINST INFECTIONS, THESE EMERGING VIRUSES REPRESENT A CONSIDERABLE THREAT TO GLOBAL PUBLIC HEALTH. WHILE THERE IS NO VIRUS-SPECIFIC TREATMENT, EVIDENCE INDICATES THAT NEUTRALIZING ANTIBODIES (ABS) CAN CONTROL HANTAVIRUS INFECTIONS IN HUMANS. STUDIES ALSO SHOW THAT SOME HFRS AND HCPS PATIENTS POSSESS ABS THAT CAN CROSS-NEUTRALIZE HETEROLOGOUS STRAINS. THUS, WE HYPOTHESIZE THAT SOME HPCS AND HFRS CONVALESCENT PATIENTS EVOLVE ABS THAT CAN BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. ICHOR BIOLOGICS HAS DEVELOPED A PLATFORM FOR THE ISOLATION OF NATURALLY-OCCURRING HUMAN MONOCLONAL ABS (MABS), WHICH WE HAVE USED TO ISOLATE SEVERAL HUNDRED HANTAVIRUS-SPECIFIC MABS FROM A COHORT OF HCPS CONVALESCENT PATIENTS. IN CHARACTERIZING THESE PATIENTS, WE OBSERVED THAT SOME PATIENTS DEVELOPED ABS THAT RECOGNIZED A HETEROLOGOUS STRAIN, SUGGESTING THAT SOME PATIENTS MAY POSSESS ABS THAT BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THEREFORE, THE PRODUCT TO BE DEVELOPED IS A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS. TO EXAMINE THE FEASIBILITY OF THIS PRODUCT, IN AIM 1 WE WILL SCREEN THE HUNDREDS OF MABS PREVIOUSLY ISOLATED FROM HCPS PATIENTS FOR THEIR CAPACITY TO NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THIS SCREEN WILL BE FACILITATED BY A BSL2-SAFE, RAPID HANTAVIRUS NEUTRALIZATION ASSAY DEVELOPED BY ICHOR BIOLOGICS. SINCE VIRUSES CAN ACQUIRE MUTATIONS THAT ALLOW THEM TO EVADE AB RESPONSES, IN AIM 2, WE WILL DETERMINE THE FUNCTIONAL EPITOPES BOUND BY ANY BROADLY NEUTRALIZING ABS IN ORDER TO IDENTIFY THE ABS THAT CAN BE COMBINED INTO A THERAPEUTIC COCKTAIL. THESE STUDIES WILL DETERMINE THE POTENTIAL FOR DEVELOPING A BROADLY NEUTRALIZING AB-BASED THERAPEUTIC FROM HANTAVIRUS CONVALESCENT PATIENTS AND ACCELERATE THE COMMERCIALIZATION OF ANY THERAPEUTIC FOR USE IN THE CLINIC. CONSIDERING THE HIGH SAFETY AND EFFICACY PROFILES OF BIOLOGICS, PLUS OUR STRONG POSITIONING IN THE HANTAVIRUS SPACE (E.G. STRONG SCIENTIFIC, LEGAL AND BUSINESS ADVISORS, AND CHILEAN GOVERNMENT FUNDING), WE ARE UNIQUELY SITUATED TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS.
$0
12/6/21
Not listed
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS - PROJECT SUMMARY HANTAVIRUSES ARE AN EMERGING FAMILY OF HIGHLY PATHOGENIC VIRUSES THAT CAUSE 100-200,000 CASES OF TWO SEVERE FEBRILE ILLNESSES A YEAR; HANTAVIRUS CARDIOPULMONARY SYNDROME (HCPS) AND HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS). WHILE THE ANNUAL INCIDENCE OF INFECTIONS ARE RELATIVELY LOW COMPARED TO OTHER VIRAL INFECTIONS, SOME HANTAVIRUS STRAINS ARE PARTICULARLY DEADLY, CAUSING A 35-40% MORTALITY RATE IN OTHERWISE HEALTHY YOUNG ADULTS. IN FACT, BECAUSE OF THEIR HIGH MORTALITY RATES HANTAVIRUSES ARE CONSIDERED A POTENTIAL BIOTERRORISM AGENT BY THE NIH, CDC AND THE DEPARTMENT OF DEFENSE. COUPLED WITH THE FACT THAT THERE IS NO VIRUS-SPECIFIC TREATMENT OR GLOBALLY APPROVED VACCINE TO PROTECT AGAINST INFECTIONS, THESE EMERGING VIRUSES REPRESENT A CONSIDERABLE THREAT TO GLOBAL PUBLIC HEALTH. WHILE THERE IS NO VIRUS-SPECIFIC TREATMENT, EVIDENCE INDICATES THAT NEUTRALIZING ANTIBODIES (ABS) CAN CONTROL HANTAVIRUS INFECTIONS IN HUMANS. STUDIES ALSO SHOW THAT SOME HFRS AND HCPS PATIENTS POSSESS ABS THAT CAN CROSS-NEUTRALIZE HETEROLOGOUS STRAINS. THUS, WE HYPOTHESIZE THAT SOME HPCS AND HFRS CONVALESCENT PATIENTS EVOLVE ABS THAT CAN BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. ICHOR BIOLOGICS HAS DEVELOPED A PLATFORM FOR THE ISOLATION OF NATURALLY-OCCURRING HUMAN MONOCLONAL ABS (MABS), WHICH WE HAVE USED TO ISOLATE SEVERAL HUNDRED HANTAVIRUS-SPECIFIC MABS FROM A COHORT OF HCPS CONVALESCENT PATIENTS. IN CHARACTERIZING THESE PATIENTS, WE OBSERVED THAT SOME PATIENTS DEVELOPED ABS THAT RECOGNIZED A HETEROLOGOUS STRAIN, SUGGESTING THAT SOME PATIENTS MAY POSSESS ABS THAT BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THEREFORE, THE PRODUCT TO BE DEVELOPED IS A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS. TO EXAMINE THE FEASIBILITY OF THIS PRODUCT, IN AIM 1 WE WILL SCREEN THE HUNDREDS OF MABS PREVIOUSLY ISOLATED FROM HCPS PATIENTS FOR THEIR CAPACITY TO NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THIS SCREEN WILL BE FACILITATED BY A BSL2-SAFE, RAPID HANTAVIRUS NEUTRALIZATION ASSAY DEVELOPED BY ICHOR BIOLOGICS. SINCE VIRUSES CAN ACQUIRE MUTATIONS THAT ALLOW THEM TO EVADE AB RESPONSES, IN AIM 2, WE WILL DETERMINE THE FUNCTIONAL EPITOPES BOUND BY ANY BROADLY NEUTRALIZING ABS IN ORDER TO IDENTIFY THE ABS THAT CAN BE COMBINED INTO A THERAPEUTIC COCKTAIL. THESE STUDIES WILL DETERMINE THE POTENTIAL FOR DEVELOPING A BROADLY NEUTRALIZING AB-BASED THERAPEUTIC FROM HANTAVIRUS CONVALESCENT PATIENTS AND ACCELERATE THE COMMERCIALIZATION OF ANY THERAPEUTIC FOR USE IN THE CLINIC. CONSIDERING THE HIGH SAFETY AND EFFICACY PROFILES OF BIOLOGICS, PLUS OUR STRONG POSITIONING IN THE HANTAVIRUS SPACE (E.G. STRONG SCIENTIFIC, LEGAL AND BUSINESS ADVISORS, AND CHILEAN GOVERNMENT FUNDING), WE ARE UNIQUELY SITUATED TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS.
$0
12/6/21
Not listed
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS - PROJECT SUMMARY HANTAVIRUSES ARE AN EMERGING FAMILY OF HIGHLY PATHOGENIC VIRUSES THAT CAUSE 100-200,000 CASES OF TWO SEVERE FEBRILE ILLNESSES A YEAR; HANTAVIRUS CARDIOPULMONARY SYNDROME (HCPS) AND HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS). WHILE THE ANNUAL INCIDENCE OF INFECTIONS ARE RELATIVELY LOW COMPARED TO OTHER VIRAL INFECTIONS, SOME HANTAVIRUS STRAINS ARE PARTICULARLY DEADLY, CAUSING A 35-40% MORTALITY RATE IN OTHERWISE HEALTHY YOUNG ADULTS. IN FACT, BECAUSE OF THEIR HIGH MORTALITY RATES HANTAVIRUSES ARE CONSIDERED A POTENTIAL BIOTERRORISM AGENT BY THE NIH, CDC AND THE DEPARTMENT OF DEFENSE. COUPLED WITH THE FACT THAT THERE IS NO VIRUS-SPECIFIC TREATMENT OR GLOBALLY APPROVED VACCINE TO PROTECT AGAINST INFECTIONS, THESE EMERGING VIRUSES REPRESENT A CONSIDERABLE THREAT TO GLOBAL PUBLIC HEALTH. WHILE THERE IS NO VIRUS-SPECIFIC TREATMENT, EVIDENCE INDICATES THAT NEUTRALIZING ANTIBODIES (ABS) CAN CONTROL HANTAVIRUS INFECTIONS IN HUMANS. STUDIES ALSO SHOW THAT SOME HFRS AND HCPS PATIENTS POSSESS ABS THAT CAN CROSS-NEUTRALIZE HETEROLOGOUS STRAINS. THUS, WE HYPOTHESIZE THAT SOME HPCS AND HFRS CONVALESCENT PATIENTS EVOLVE ABS THAT CAN BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. ICHOR BIOLOGICS HAS DEVELOPED A PLATFORM FOR THE ISOLATION OF NATURALLY-OCCURRING HUMAN MONOCLONAL ABS (MABS), WHICH WE HAVE USED TO ISOLATE SEVERAL HUNDRED HANTAVIRUS-SPECIFIC MABS FROM A COHORT OF HCPS CONVALESCENT PATIENTS. IN CHARACTERIZING THESE PATIENTS, WE OBSERVED THAT SOME PATIENTS DEVELOPED ABS THAT RECOGNIZED A HETEROLOGOUS STRAIN, SUGGESTING THAT SOME PATIENTS MAY POSSESS ABS THAT BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THEREFORE, THE PRODUCT TO BE DEVELOPED IS A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS. TO EXAMINE THE FEASIBILITY OF THIS PRODUCT, IN AIM 1 WE WILL SCREEN THE HUNDREDS OF MABS PREVIOUSLY ISOLATED FROM HCPS PATIENTS FOR THEIR CAPACITY TO NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THIS SCREEN WILL BE FACILITATED BY A BSL2-SAFE, RAPID HANTAVIRUS NEUTRALIZATION ASSAY DEVELOPED BY ICHOR BIOLOGICS. SINCE VIRUSES CAN ACQUIRE MUTATIONS THAT ALLOW THEM TO EVADE AB RESPONSES, IN AIM 2, WE WILL DETERMINE THE FUNCTIONAL EPITOPES BOUND BY ANY BROADLY NEUTRALIZING ABS IN ORDER TO IDENTIFY THE ABS THAT CAN BE COMBINED INTO A THERAPEUTIC COCKTAIL. THESE STUDIES WILL DETERMINE THE POTENTIAL FOR DEVELOPING A BROADLY NEUTRALIZING AB-BASED THERAPEUTIC FROM HANTAVIRUS CONVALESCENT PATIENTS AND ACCELERATE THE COMMERCIALIZATION OF ANY THERAPEUTIC FOR USE IN THE CLINIC. CONSIDERING THE HIGH SAFETY AND EFFICACY PROFILES OF BIOLOGICS, PLUS OUR STRONG POSITIONING IN THE HANTAVIRUS SPACE (E.G. STRONG SCIENTIFIC, LEGAL AND BUSINESS ADVISORS, AND CHILEAN GOVERNMENT FUNDING), WE ARE UNIQUELY SITUATED TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS.
$0
11/19/20
Not listed
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS - PROJECT SUMMARY HANTAVIRUSES ARE AN EMERGING FAMILY OF HIGHLY PATHOGENIC VIRUSES THAT CAUSE 100-200,000 CASES OF TWO SEVERE FEBRILE ILLNESSES A YEAR; HANTAVIRUS CARDIOPULMONARY SYNDROME (HCPS) AND HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS). WHILE THE ANNUAL INCIDENCE OF INFECTIONS ARE RELATIVELY LOW COMPARED TO OTHER VIRAL INFECTIONS, SOME HANTAVIRUS STRAINS ARE PARTICULARLY DEADLY, CAUSING A 35-40% MORTALITY RATE IN OTHERWISE HEALTHY YOUNG ADULTS. IN FACT, BECAUSE OF THEIR HIGH MORTALITY RATES HANTAVIRUSES ARE CONSIDERED A POTENTIAL BIOTERRORISM AGENT BY THE NIH, CDC AND THE DEPARTMENT OF DEFENSE. COUPLED WITH THE FACT THAT THERE IS NO VIRUS-SPECIFIC TREATMENT OR GLOBALLY APPROVED VACCINE TO PROTECT AGAINST INFECTIONS, THESE EMERGING VIRUSES REPRESENT A CONSIDERABLE THREAT TO GLOBAL PUBLIC HEALTH. WHILE THERE IS NO VIRUS-SPECIFIC TREATMENT, EVIDENCE INDICATES THAT NEUTRALIZING ANTIBODIES (ABS) CAN CONTROL HANTAVIRUS INFECTIONS IN HUMANS. STUDIES ALSO SHOW THAT SOME HFRS AND HCPS PATIENTS POSSESS ABS THAT CAN CROSS-NEUTRALIZE HETEROLOGOUS STRAINS. THUS, WE HYPOTHESIZE THAT SOME HPCS AND HFRS CONVALESCENT PATIENTS EVOLVE ABS THAT CAN BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. ICHOR BIOLOGICS HAS DEVELOPED A PLATFORM FOR THE ISOLATION OF NATURALLY-OCCURRING HUMAN MONOCLONAL ABS (MABS), WHICH WE HAVE USED TO ISOLATE SEVERAL HUNDRED HANTAVIRUS-SPECIFIC MABS FROM A COHORT OF HCPS CONVALESCENT PATIENTS. IN CHARACTERIZING THESE PATIENTS, WE OBSERVED THAT SOME PATIENTS DEVELOPED ABS THAT RECOGNIZED A HETEROLOGOUS STRAIN, SUGGESTING THAT SOME PATIENTS MAY POSSESS ABS THAT BROADLY NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THEREFORE, THE PRODUCT TO BE DEVELOPED IS A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS. TO EXAMINE THE FEASIBILITY OF THIS PRODUCT, IN AIM 1 WE WILL SCREEN THE HUNDREDS OF MABS PREVIOUSLY ISOLATED FROM HCPS PATIENTS FOR THEIR CAPACITY TO NEUTRALIZE MULTIPLE HANTAVIRUS STRAINS. THIS SCREEN WILL BE FACILITATED BY A BSL2-SAFE, RAPID HANTAVIRUS NEUTRALIZATION ASSAY DEVELOPED BY ICHOR BIOLOGICS. SINCE VIRUSES CAN ACQUIRE MUTATIONS THAT ALLOW THEM TO EVADE AB RESPONSES, IN AIM 2, WE WILL DETERMINE THE FUNCTIONAL EPITOPES BOUND BY ANY BROADLY NEUTRALIZING ABS IN ORDER TO IDENTIFY THE ABS THAT CAN BE COMBINED INTO A THERAPEUTIC COCKTAIL. THESE STUDIES WILL DETERMINE THE POTENTIAL FOR DEVELOPING A BROADLY NEUTRALIZING AB-BASED THERAPEUTIC FROM HANTAVIRUS CONVALESCENT PATIENTS AND ACCELERATE THE COMMERCIALIZATION OF ANY THERAPEUTIC FOR USE IN THE CLINIC. CONSIDERING THE HIGH SAFETY AND EFFICACY PROFILES OF BIOLOGICS, PLUS OUR STRONG POSITIONING IN THE HANTAVIRUS SPACE (E.G. STRONG SCIENTIFIC, LEGAL AND BUSINESS ADVISORS, AND CHILEAN GOVERNMENT FUNDING), WE ARE UNIQUELY SITUATED TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE A BROADLY NEUTRALIZING AB(S) THERAPEUTIC TO TREAT HCPS AND HFRS CAUSED BY HANTAVIRUS INFECTIONS.
$0
11/19/20
Not listed
DEVELOPMENT OF BROADLY NEUTRALIZING ANTIBODIES TO TREAT HANTAVIRUS INFECTIONS
$0
9/17/20